Cargando…

Epidemiology of multiple sclerosis: results from a large observational study in the UK

Multiple sclerosis (MS) progression to mortality may not be solely determined by the underlying autoimmune process. We conducted a study in a large cohort of MS patients with the aim of describing characteristics of MS patients and identification of predictors for all-cause mortality in this patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Jick, Susan S., Li, L., Falcone, G. J., Vassilev, Z. P., Wallander, M.-A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4768220/
https://www.ncbi.nlm.nih.gov/pubmed/26067217
http://dx.doi.org/10.1007/s00415-015-7796-2
_version_ 1782417910968352768
author Jick, Susan S.
Li, L.
Falcone, G. J.
Vassilev, Z. P.
Wallander, M.-A.
author_facet Jick, Susan S.
Li, L.
Falcone, G. J.
Vassilev, Z. P.
Wallander, M.-A.
author_sort Jick, Susan S.
collection PubMed
description Multiple sclerosis (MS) progression to mortality may not be solely determined by the underlying autoimmune process. We conducted a study in a large cohort of MS patients with the aim of describing characteristics of MS patients and identification of predictors for all-cause mortality in this patient group. We performed a retrospective analysis of primary care data from the UK Clinical Practice Research Datalink. Incident MS cases diagnosed between 1993 and 2006 were identified and validated using electronic and original medical records. Patients were followed to identify deaths; hazard ratios (HRs) and 95 % confidence intervals (CIs) were estimated using Cox proportional regression with age as time-scale. In total, 1713 incident MS cases were identified. Following MS diagnosis, frequent comorbidities were infections (80 %), and depression (46 %). Adjusted HRs (95 % CIs) for all-cause mortality were: 2.0 (1.2–3.4) for current smoking; 7.6 (3.2–17.7) for alcohol abuse; 2.7 (1.6–4.5) for pneumonia and influenza; 4.1 (2.7–6.3) for urinary tract infections; 2.2 (1.2–4.2) for heart disease and 4.9 (2.9–8.0) for cancer. Our results suggest that MS survival is influenced not only by the underlying autoimmune process, but also by patient comorbidities and lifestyle factors. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00415-015-7796-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4768220
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-47682202016-03-29 Epidemiology of multiple sclerosis: results from a large observational study in the UK Jick, Susan S. Li, L. Falcone, G. J. Vassilev, Z. P. Wallander, M.-A. J Neurol Original Communication Multiple sclerosis (MS) progression to mortality may not be solely determined by the underlying autoimmune process. We conducted a study in a large cohort of MS patients with the aim of describing characteristics of MS patients and identification of predictors for all-cause mortality in this patient group. We performed a retrospective analysis of primary care data from the UK Clinical Practice Research Datalink. Incident MS cases diagnosed between 1993 and 2006 were identified and validated using electronic and original medical records. Patients were followed to identify deaths; hazard ratios (HRs) and 95 % confidence intervals (CIs) were estimated using Cox proportional regression with age as time-scale. In total, 1713 incident MS cases were identified. Following MS diagnosis, frequent comorbidities were infections (80 %), and depression (46 %). Adjusted HRs (95 % CIs) for all-cause mortality were: 2.0 (1.2–3.4) for current smoking; 7.6 (3.2–17.7) for alcohol abuse; 2.7 (1.6–4.5) for pneumonia and influenza; 4.1 (2.7–6.3) for urinary tract infections; 2.2 (1.2–4.2) for heart disease and 4.9 (2.9–8.0) for cancer. Our results suggest that MS survival is influenced not only by the underlying autoimmune process, but also by patient comorbidities and lifestyle factors. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00415-015-7796-2) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2015-06-13 2015 /pmc/articles/PMC4768220/ /pubmed/26067217 http://dx.doi.org/10.1007/s00415-015-7796-2 Text en © The Author(s) 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Communication
Jick, Susan S.
Li, L.
Falcone, G. J.
Vassilev, Z. P.
Wallander, M.-A.
Epidemiology of multiple sclerosis: results from a large observational study in the UK
title Epidemiology of multiple sclerosis: results from a large observational study in the UK
title_full Epidemiology of multiple sclerosis: results from a large observational study in the UK
title_fullStr Epidemiology of multiple sclerosis: results from a large observational study in the UK
title_full_unstemmed Epidemiology of multiple sclerosis: results from a large observational study in the UK
title_short Epidemiology of multiple sclerosis: results from a large observational study in the UK
title_sort epidemiology of multiple sclerosis: results from a large observational study in the uk
topic Original Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4768220/
https://www.ncbi.nlm.nih.gov/pubmed/26067217
http://dx.doi.org/10.1007/s00415-015-7796-2
work_keys_str_mv AT jicksusans epidemiologyofmultiplesclerosisresultsfromalargeobservationalstudyintheuk
AT lil epidemiologyofmultiplesclerosisresultsfromalargeobservationalstudyintheuk
AT falconegj epidemiologyofmultiplesclerosisresultsfromalargeobservationalstudyintheuk
AT vassilevzp epidemiologyofmultiplesclerosisresultsfromalargeobservationalstudyintheuk
AT wallanderma epidemiologyofmultiplesclerosisresultsfromalargeobservationalstudyintheuk